drugset
drugset / Trial / NCT04821765

Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer

NCT04821765 ↗

Phase 2 Completed 35 enrolled Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NaSingle-groupOpen-labelTreatment

Summary

Chemoradiotherapy（CRT） is the main treatment for esophageal cancer patients with recurrent desease，and checkpoint blockade (PD-1) have been shown to be effective in advanced esophageal cancer. Therefore, PD-1 combined with chemoradiotherapy （CRT）may further improve the efficacy and become a new method for the treatment of esophageal cancer.This study intends to conduct a single-arm, prospective clinical study, aiming to evaluate the safety and efficacy of PD-1 combined with chemoradiotherapy(CRT) in patients with oligometastatic esophageal squamous cell carcinoma.

Timeline

Start
2020-10-01
Primary completion
2023-06-30
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Albumin-Bound Paclitaxel Unknown 150 mg/m2 —
Subject Cisplatin Other / unclassified 75 mg/m2 —
Subject Tislelizumab Monoclonal antibody 200 mg —

Indications

esophageal squamous cell carcinoma